Glaucoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Glaucoma signs and symptoms include eye pain, nausea and vomiting (accompanying the severe eye pain), sudden onset of visual disturbance, often in low light, blurred vision, and reddening of the eye.
The Glaucoma pipeline drugs market research report provides an analysis of the Glaucoma drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The guide also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Glaucoma and features dormant and discontinued projects.
Key Targets of the Glaucoma Pipeline Drugs Market
Some of the targets of the Glaucoma pipeline drugs market are Prostaglandin F2 Alpha Receptor, Rho Kinase, Beta 1 Adrenergic Receptor, Cannabinoid Receptor 2, Beta 2 Adrenergic Receptor, Cannabinoid Receptor 1, Soluble Guanylate Cyclas, cGMP Specific 3′,5′ Cyclic Phosphodiesterase, Alpha 2 Adrenergic Receptor, Amyloid Beta A4 Protein, and Angiopoietin 1 Receptor among others.
Glaucoma Pipeline Drugs Market, by Key Targets
For more insights on key targets, download a free report sample
Key Mechanisms of Action in the Glaucoma Pipeline Drugs Market
The key mechanisms of action of the Glaucoma pipeline drugs market are Prostaglandin F2 Alpha Receptor Agonist, Rho Kinase Inhibitor, Beta 1 Adrenergic Receptor Antagonist, Cannabinoid Receptor 2 Agonist, Cannabinoid Receptor 1 Agonist, Soluble Guanylate Cyclase Activator, Beta 2 Adrenergic Receptor Antagonist, cGMP Specific 3′,5′ Cyclic Phosphodiesterase Inhibitor, Amyloid Beta A4 Protein Inhibitor, Alpha 2 Adrenergic Receptor Agonist, and Angiopoietin 1 Receptor Agonist.
Glaucoma Pipeline Drugs Market, by Key Mechanisms of Action
For more insights on key mechanisms of action, download a free report sample
Key Routes of Administration in the Glaucoma Pipeline Drugs Market
The routes of administration in the Glaucoma pipeline drugs market are ophthalmic, intraocular, intravitreal, oral, parenteral, intravenous, topical, transdermal, subcutaneous, inhalational, nasal, and sublingual among others.
Glaucoma Pipeline Drugs Market, by Routes of Administration
For more insights on routes of administration, download a free report sample
Key Molecule Types in the Glaucoma Pipeline Drugs Market
The molecule types in the Glaucoma pipeline drugs market are Small Molecule, Gene Therapy, Antisense RNAi Oligonucleotide, Monoclonal Antibody, Recombinant Protein, Synthetic Peptide, and Biologic.
Glaucoma Pipeline Drugs Market, by Molecule Types
For more insights on molecule type, download a free report sample
Key Companies in the Glaucoma Pipeline Drugs Market
Some of the key companies in the Glaucoma pipeline drugs market are NicOx SA, Santen Pharmaceutical Co Ltd, Intratus Inc, Graybug Vision Inc, Ocular Therapeutix Inc, Aerie Pharmaceuticals Inc, Astellas Pharma Inc, DHP Korea Co Ltd, Laboratoires Thea SA, and SIFI SpA among others.
Glaucoma Pipeline Drugs Market, by Companies
For more insights on companies, download a free report sample
Glaucoma Pipeline Drugs Market Report Overview
Key Targets | Prostaglandin F2 Alpha Receptor, Rho Kinase, Beta 1 Adrenergic Receptor, Cannabinoid Receptor 2, Beta 2 Adrenergic Receptor, Cannabinoid Receptor 1, Soluble Guanylate Cyclas, cGMP Specific 3′,5′ Cyclic Phosphodiesterase, Alpha 2 Adrenergic Receptor, Amyloid Beta A4 Protein and Angiopoietin 1 Receptor |
Key Mechanisms of Action | Prostaglandin F2 Alpha Receptor Agonist, Rho Kinase Inhibitor, Beta 1 Adrenergic Receptor Antagonist, Cannabinoid Receptor 2 Agonist, Cannabinoid Receptor 1 Agonist, Soluble Guanylate Cyclase Activator, Beta 2 Adrenergic Receptor Antagonist, cGMP Specific 3′,5′ Cyclic Phosphodiesterase Inhibitor, Amyloid Beta A4 Protein Inhibitor, Alpha 2 Adrenergic Receptor Agonist, and Angiopoietin 1 Receptor Agonist |
Key Routes of Administration | Ophthalmic, Intraocular, Intravitreal, Oral, Parenteral, Intravenous, Topical, Transdermal, Subcutaneous, Inhalational, Nasal and Sublingual |
Key Molecule Types | Small Molecule, Gene Therapy, Antisense RNAi Oligonucleotide, Monoclonal Antibody, Recombinant Protein, Synthetic Peptide, and Biologic |
Key Companies | NicOx SA, Santen Pharmaceutical Co Ltd, Intratus Inc, Graybug Vision Inc, Ocular Therapeutix Inc, Aerie Pharmaceuticals Inc, Astellas Pharma Inc, DHP Korea Co Ltd, Laboratoires Thea SA, and SIFI SpA |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Glaucoma (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Glaucoma (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Glaucoma (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Glaucoma (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Glaucoma (Ophthalmology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Glaucoma (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Glaucoma (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Aadi Bioscience Inc
AbbVie Inc
AC Immune SA
Adtech Pharma Inc
Advanced Vision Technologies (New York)
Aerie Pharmaceuticals Inc
Amgen Inc
Annexon Inc
Annovis Bio Inc
APIRx Pharmaceuticals USA LLC
Arctic Vision Shanghai Biotechnology Co Ltd
Astellas Pharma Inc
Avirmax Inc
Betaliq Inc
Bial - Portela & Ca SA
Biozeus Pharmaceutical SA
Broadwing Bio
BSIM Therapeutics SA
Calpain Therapeutics Pty Ltd
Cellix Bio Pvt Ltd
Certa Therapeutics Pty Ltd
Character Biosciences Co
Chong Kun Dang Pharmaceutical Corp
Cloudbreak Therapeutics LLC
Connexin Therapeutics Inc
Curigin Co Ltd
D. Western Therapeutics Institute Inc
Deha Pharmaceutical LLC
DHP Korea Co Ltd
Disarm Therapeutics Inc
Dompe Farmaceutici SpA
DTx Pharma Inc
Emerald Organic Products Inc
Emmecell LLC
Evotec SE
Eye Bio Korea Co Ltd
EyePoint Pharmaceuticals Inc
Eyevensys SAS
FasT Biopharma Ltd
Future Medicine Co Ltd
Galimedix Therapeutics Ltd
Glaukos Corp
Graybug Vision Inc
Guangzhou Cellprotek Pharmaceutical Co Ltd
Guangzhou Magpie Pharmaceutical Co Ltd
Gurus BioPharm Inc
Handok Inc
HitGen Inc
HK inno.N Corp
ID Pharma Co Ltd
Iduna Therapeutics Inc
Ildong Pharmaceutical Co Ltd
InMed Pharmaceuticals Inc
Intratus Inc
Isarna Therapeutics GmbH
jCyte Inc
Jenivision Inc
Kodiak Sciences Inc
Kowa Co Ltd
Kukje Pharmaceutical Industry Co Ltd
Kyorin Pharmaceutical Co Ltd
Laboratoires Thea SA
Laboratorios Salvat SA
Laboratorios Sophia SA de CV
LayerBio Inc
Lee's Pharmaceutical Holdings Ltd
Life Biosciences LLC
Luminus Biosciences Inc
Matrix Biomed Inc
MediPrint Ophthalmics Inc
MeiraGTx Holdings Plc
MimeTech Srl
Mitotech SA
MyX Therapeutics Inc
NeurAegis Inc
Neuraly Inc
Neurim Pharmaceuticals Ltd
Neurizon Pharma GBR
Neurophth Therapeutics Inc
Neuroptika Inc
NeuroScientific Biopharmaceuticals Ltd
Nexel Co Ltd
NicOx SA
NoNO Inc
Novaliq GmbH
Novartis AG
Noveome Biotherapeutics Inc
Novoron Bioscience Inc
OccuRx Pty Ltd
Ocular Therapeutix Inc
Oculis SA
Oculo Therapy LLC
Ocuphire Pharma Inc
Oncolys BioPharma Inc
ONL Therapeutics Inc
Perceive Biotherapeutics Inc
pH Pharma Co Ltd
PharmaDrug Inc
Pinotbio Inc
PolyActiva Pty Ltd
Profarma
Q BioMed Inc
Qlaris Bio Inc
Quark Pharmaceuticals Inc
Qurgen Inc
Radikal Therapeutics Inc
Rebio Technologies Ltd
Rebus Holdings Inc
Regeneron Pharmaceuticals Inc
ReNetX Bio
Retinset SL
Reven Holdings Inc
Ripple therapeutics Corp
Santen Pharmaceutical Co Ltd
Senju Pharmaceutical Co Ltd
SIFI SpA
Skye Bioscience Inc
Stuart Therapeutics Inc
Sun Pharma Advanced Research Company Ltd
Sun Pharmaceutical Industries Ltd
Sustained Nano Systems LLC
Sylentis SAU
TaeJoon Pharmaceuticals Co Ltd
TALLC Inc
Tarsius Pharma Ltd
TearClear Corp
Teraclon IDF SL
TikoMed AB
Toa Eiyo Ltd
Topadur Pharma AG
ViSci Ltd
Visus Therapeutics Inc
Viva Vision Biotech
Whitecap Biosciences LLC
Xilingyuan Pharmaceutical Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the targets of the Glaucoma pipeline drugs market?
Some of the targets of the Glaucoma pipeline drugs market are Prostaglandin F2 Alpha Receptor, Rho Kinase, Beta 1 Adrenergic Receptor, Cannabinoid Receptor 2, Beta 2 Adrenergic Receptor, Cannabinoid Receptor 1, Soluble Guanylate Cyclas, cGMP Specific 3′,5′ Cyclic Phosphodiesterase, Alpha 2 Adrenergic Receptor, Amyloid Beta A4 Protein and Angiopoietin 1 Receptor.
-
What are the mechanisms of action of the Glaucoma pipeline drugs market?
The key mechanism of action of the Glaucoma pipeline drugs market are Prostaglandin F2 Alpha Receptor Agonist, Rho Kinase Inhibitor, Beta 1 Adrenergic Receptor Antagonist, Cannabinoid Receptor 2 Agonist, Cannabinoid Receptor 1 Agonist, Soluble Guanylate Cyclase Activator, Beta 2 Adrenergic Receptor Antagonist, cGMP Specific 3′,5′ Cyclic Phosphodiesterase Inhibitor, Amyloid Beta A4 Protein Inhibitor, Alpha 2 Adrenergic Receptor Agonist, and Angiopoietin 1 Receptor Agonist.
-
What are the routes of administration in the Glaucoma pipeline drugs market?
The routes of administration in the Glaucoma pipeline drugs market are ophthalmic, intraocular, intravitreal, oral, parenteral, intravenous, topical, transdermal, subcutaneous, inhalational, nasal and sublingual.
-
What are the molecule types in the Glaucoma pipeline drugs market?
The molecule types in the Glaucoma pipeline drugs market are Small Molecule, Gene Therapy, Antisense RNAi Oligonucleotide, Monoclonal Antibody, Recombinant Protein, Synthetic Peptide, and Biologic.
-
Which are the key companies in the Glaucoma pipeline drugs market?
Some of the key companies in the Glaucoma pipeline drugs market are NicOx SA, Santen Pharmaceutical Co Ltd, Intratus Inc, Graybug Vision Inc, Ocular Therapeutix Inc, Aerie Pharmaceuticals Inc, Astellas Pharma Inc, DHP Korea Co Ltd, Laboratoires Thea SA, and SIFI SpA among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.